The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss), including portion attributable to noncontrolling interest | -15,189 |
| Stock option compensation expense | 2,965 |
| Common stock issued for services | 648 |
| Credit loss expense | 3,886 |
| Operating lease right-of-use assets amortization | 148 |
| Finance lease right -of-use asset amortization | 113 |
| Operating lease liabilities, net | -137 |
| Finance lease liability, net | 88 |
| Interest expense related to amortization of the discount on note payable | 196 |
| Fair value of warrants issued for a fee and interest | 0 |
| Loss on investment in south korean joint venture | -14 |
| Ppp forgiveness | 0 |
| Depreciation expense | 145 |
| Accounts receivable | 1,814 |
| Inventories | -20 |
| Prepaid expenses and other assets | 226 |
| Accounts payable and accrued expenses-Entities Excluding Partially Owned Subsidiary | 266 |
| Deposits | 99 |
| Accounts payable and accrued expenses-Partially Owned Subsidiary | 377 |
| Contract liabilities | 280 |
| Net cash used in operating activities | -8,297 |
| Equipment purchases | 46 |
| Clyra medical note receivable | 0 |
| Repayment of note receivable | 481 |
| Net cash provided by (used in) investing activities | 435 |
| Proceeds from sale of common stock, net of offering costs | 2,027 |
| Proceeds from biolargo stock option exercise | 0 |
| Proceeds from biolargo warrant exercise-Biolargo Energy Technologies Inc BETI | 0 |
| Proceeds (repayments) from debt obligations, net | 24 |
| Proceeds from sale of preferred stock in clyra medical-Partially Owned Subsidiary | 2,145 |
| Proceeds from sale of common stock, net of offering costs-Clyra Medical Common Stock | 445 |
| Proceeds from biolargo warrant exercise-Clyra Medical Technologies | 1,894 |
| Proceeds from clyra medical note payable-Partially Owned Subsidiary | 1,261 |
| Proceeds from sale of common stock, net of offering costs-Beti Common Stock | 425 |
| Net cash provided by financing activities | 8,221 |
| Net effect of foreign currency translation | -24 |
| Net change in cash | 335 |
| Cash at beginning of year | 3,548 |
| Cash at end of year | 3,883 |
BIOLARGO, INC. (BLGO)
BIOLARGO, INC. (BLGO)